Storm Therapeutics Revenue and Competitors

Cambridge,

Location

#7044

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Storm Therapeutics's estimated annual revenue is currently $7.4M per year.(i)
  • Storm Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Storm Therapeutics has 48 Employees.(i)
  • Storm Therapeutics grew their employee count by 12% last year.

Storm Therapeutics's People

NameTitleEmail/Phone
1
Chief Business OfficerReveal Email/Phone
2
CEO and PresidentReveal Email/Phone
3
CEO & PresidentReveal Email/Phone
4
VP, Medicinal ChemistryReveal Email/Phone
5
SVP TherapeuticsReveal Email/Phone
6
Head Discovery BiologyReveal Email/Phone
7
Director Pharmacology and Cancer Drug DiscoveryReveal Email/Phone
8
Director RNA AnalyticsReveal Email/Phone
9
Director, Translational OncologyReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Storm Therapeutics?

STORM Therapeutics (www.stormtherapeutics.com) is a spin out company translating the groundbreaking work in RNA epigenetics of Prof Tony Kouzarides and Prof Eric Miska of the Gurdon Institute, University of Cambridge into the discovery of first in class drugs in oncology and other diseases Several large families of RNA-modifying enzymes have been identified that impact key biological processes by changing the activity of RNA through catalysing epigenetic RNA modifications. Advances in the understanding of RNA modification and its role in the development of cancer offer the prospect of exploring novel therapeutic targets and potential discovery and development of first-in-class products. STORM is working at the forefront of this new field. The company draws on its unique insights to develop candidate drug molecules for the treatment of specific cancers with high unmet medical need. Since inception in May 2015, Storm has raised over $50m in funding. Storm is backed by blue chip investors Merck Ventures, Pfizer Ventures, IP Group, Cambridge Innovation Capital, Seroba and Taiho Ventures, who share the founders' ambitions to build a world leading company in the field. The company occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Storm Therapeutics News

2022-04-19 - FemTech is taking the world by storm - except in Israel

... crowdfunding platforms and not through [investment or venture capital] funds,” said Efrat Ramati, the CEO of Algamed Therapeutics.

2022-03-30 - COVID-19 therapeutics: Challenges and directions for the future

Anti-inflammatory Therapies. In common with other respiratory viruses, SARS-CoV-2 induces a “cytokine storm” or “cytokine release syndrome” in...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$59.4M48-51%$63.9M
#2
$9.6M484%N/A
#3
$3.7M48-21%$42M
#4
$7.4M4830%N/A
#5
$6.9M48N/AN/A